T3D Therapeutics Blog T3D Therapeutics Begins Enrollment in the PIONEER Phase 2 Clinical Trial of T3D-959 in Patients with Mild to Moderate Alzheimer's Disease

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2020 - T3D Therapeutics, Inc. ("T3D" ), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced today the initiation of screening and enrollment for the PIONEER Phase 2 clinical trial for its product candidate T3D-959. T3D-959 [...]